BCI Pharma

Executive Summary

BCI Pharma, now rebranding as Hirundo Biosciences, is a private French biotechnology company founded in 2003 and headquartered in Paris. The company operates in the small molecules sector, focusing on the discovery and development of novel therapeutics. Despite its long history, BCI Pharma has maintained a low public profile, with no disclosed pipeline, funding rounds, or clinical-stage assets. The ongoing rebranding to Hirundo Biosciences, including a new website and corporate identity, signals a strategic refresh aimed at revitalizing the company's presence and potentially repositioning its therapeutic focus. As of early 2026, BCI Pharma remains in a pre-revenue stage with no approved products or disclosed collaborators. The lack of publicly available pipeline data makes it difficult to assess its technological platform or competitive positioning. The rebranding effort may precede a relaunch with new programs or partnerships, but until concrete developments emerge, the company's near-term outlook is uncertain. Its low profile and absence of recent news suggest limited near-term catalysts, though the completion of the rebranding could pave the way for future announcements.

Upcoming Catalysts (preview)

• Q3 2026Completion of Rebranding to Hirundo Biosciences90% success